CSL Vifor explained

CSL Vifor
Founded:1927[1]
Type:Public
Hq Location Country:Switzerland
Areas Served:Worldwide
Key People:Hervé Gisserot (General Manager)[2]
Revenue: CHF 1.75 billion (2021)[3]

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

History

Activity

CSL Vifor is active in the treatment of iron deficiency and iron deficiency anaemia.[17] The Group also has a focus on the management of conditions in nephrology, cardiology and rare diseases. Iron deficiency treatments Ferinject and Injectafer were accountable for more than a third of its revenues in 2021.[18]

The dialysis segment with the Erythropoiesis-Stimulating Agents Mircera[19] (Methoxy polyethylene glycol-epoetin beta) and Retacrit (Epoetin alfa-epbx) as well as the phosphate binder Velphoro (Sucroferric oxyhydroxide) has a similarly high turnover as the iron deficiency area, which also includes the orally administered treatment Maltofer (iron polymaltose). The potassium binder Veltassa (Patiromer) is the most selling treatment in the nephrology segment.[20]

CSL Vifor is a member of a number of trade associations that advocate on behalf of the pharmaceutical industry and for the policy positions commonly shared, this includes the European Federation of Pharmaceutical Industries and Associations (EFPIA).[21] CSL Vifor has formed collaborations with pharmaceutical companies like American Regent, Roche, Fresenius Medical Care, Fresenius Kabi[22] and Pfizer. It has also partnered with biotechs such as Akebia, Angion Biomedica, Cara Therapeutics, ChemoCentryx and Travere Therapeutics.[23]

Structure and operations

CSL Vifor is present in North and South America, Europe, the Middle East and Asia Pacific and is active in over 100 countries all around the world. R&D sites of the group are located in Switzerland.[24] The company is headquartered in St. Gallen where its core manufacturing capabilities on active pharmaceutical ingredient (API) production of its iron therapies are concentrated. The operational headquarters for sales, marketing, medicine and registration are located in Glattbrugg.[19] CSL Vifor maintains a research site on iron deficiency in the Bio-Technopark in Schlieren. The Zürich-based subsidiary Inositec is an ETH spin-off. Sanifit Therapeutics is based in Palma de Mallorca.[13] In China, Vifor Fresenius Kabi is among the top 10 multinational pharmaceutical companies as a market leader in clinical nutrition, anesthesia and nephrology.[22]

CSL Vifor develops, manufactures and markets pharmaceutical products.[25] The Group's businesses include CSL Vifor, focused on iron deficiency and iron deficiency anaemia, and Vifor Fresenius Medical Care Renal Pharma, focused on kidney disease patients, including anaemia, mineral and bone management, cardio-renal conditions, and rare diseases. The second joint company of CSL Vifor with Fresenius is Vifor Fresenius Kabi focusing on marketing iron deficiency drugs in China.[26] CSL Vifor includes also Sanifit Therapeutics from Spain active in the field of calcification disorders in Chronic Kidney Disease.[27] Nephtera is a joint venture with Evotec to build a nephrology therapeutic pipeline.[28]

Therapeutic areas

Iron deficiency is a condition in which iron availability is insufficient to meet body needs. It affects one out of three women of reproductive age worldwide.[29] CSL Vifors first treatment in this area dates back to the pioneering work of pharmacist Caspar Friedrich Hausmann in 1872 in St. Gallen. Iron-deficiency anemia,[23] inflammatory bowel disease (IBD), chronic heart failure (CHF)[23] and patient blood management (PBM)[23] are conditions treated by iron-based products of CSL Vifor.

Besides Iron, the Swiss company focusses on the therapeutic areas Dialysis, Nephrology and Rare Diseases. Vifor Fresenius Medical Care Renal Pharma (VFMCRP), the joint company with Fresenius Medical Care since 2010, gives CSL Vifor access to a network of dialysis centers. It is active in the treatment of chronic kidney disease (CKD),[30] chronic kidney disease-associated pruritus,[31] renal anemia[32] and hyperphosphatemia.[33]

In the therapeutic area nephrology and rare disease, CSL Vifor specializes on hyperkalemia,[33] secondary hyperparathyroidism,[34] ANCA-associated vasculitis, beta-thalassemia[35] and sickle cell disease, CKD-associated peripheral artery disease and aortic valve stenosis,[13] focal segmental glomerulosclerosis, IgA nephropathy and cardiac surgery-associated Acute kidney injury (CSA-AKI).[23]

Products and in-Licensing

Apart from its own manufactured iron products, CSL Vifor enters partnerships and is in-licensing products at an advanced stage of development additionally to its own research and development (R&D). CSL Vifor has concluded cooperation and licensing agreements with both large pharmaceutical companies and smaller biotech companies.[36]

Commercialized Products[36]

Pipeline products[36]

Notes and References

  1. Web site: Der reichste Ebener aller Zeiten. Handelszeitung. de. 2021-12-14. 2022-05-10.
  2. Web site: After delay, CSL's $11.7B deal for Vifor poised to close next week. Fiercepharma. Kanstein. Fraiser. 2022-08-02. 2022-12-29.
  3. Web site: Vifor results show strength as CSL tender period nears end. Australian Financial Review. Redrup. Yolanda. 2022-02-18. 2022-02-28.
  4. News: Galenica says to offer $915 million for Aspreva. Reuters. 18 October 2007 . 2021-11-28.
  5. News: Galenica to buy biotech firm Relypsa for $1.5 billion, ahead of split. Reuters. 21 July 2016 . 2021-11-28.
  6. Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without Food. 2018-05-08. 2022-11-20.
  7. Web site: Media release: Swiss biotechnology – Investments at record level and outstanding success stories. Swiss Biotech. 2021-11-28.
  8. Web site: Vifor Pharma Group announces successful sale of OM Pharma. 2020-10-04. www.viforpharma.com. en.
  9. Web site: Vifor Pharma and Fresenius Kabi form joint venture in China. 2020-02-20. 2022-11-20.
  10. Web site: Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance. . 2021-08-21. 2022-11-20.
  11. Web site: Vifor Pharma in US$100m licence deal with Cara Therapeutics. 2020-10-21. 2022-11-20.
  12. Web site: Vifor Pharma reports sustained growth in 2021. 2022-02-17. 2022-11-20.
  13. Web site: Vifor Pharma Doubles Down on Kidney Disease with New Acquisitions. biospace.com. Terry. Mark. 2021-11-22. 2022-02-28.
  14. News: Australia's CSL to buy Swiss drugmaker Vifor for $11.7 bln. Reuters. 14 December 2021. Nainan. Nikhil. Koltrowitz. Silke. Murdoch. Scott. Murdoch. Scott.
  15. Web site: Australia's CSL to buy Swiss drugmaker Vifor for $11.7 bln. Reuters. Nainan. Nikhil. Koltrowitz. Silke. Murdoch. Scott. 2021-12-14. 2022-02-28.
  16. Web site: CSL share price climbs as $16 billion Vifor acquisition becomes effective. 2022-08-09. 2022-11-20.
  17. Anemia Treatment Drugs: 2019 Global Market Study; Analyzed. globenewswire.com. 26 April 2019 . 2021-11-28.
  18. Web site: Vifor results show strength as CSL tender period nears end. Australian Financial Review. Redrup. Yolanda. 2022-02-18. 2022-02-28.
  19. Web site: Vifor Fresenius Medical Care Renal Pharma . Swissbiotech. 2022-05-10.
  20. Web site: Vifor Pharma reports sustained growth in 2021. Biospace. 2022-02-17. 2022-05-10.
  21. Web site: Membership. efpia.eu. 2021-11-28.
  22. Web site: Vifor Pharma and Fresenius Kabi form joint venture in China. Pharmaceutical Technology. 2020-02-20. 2022-05-10.
  23. Web site: Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance. Bloomberg. 2021-08-05. 2022-05-10.
  24. Web site: Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World's First Research Professorship for Nanopharmaceutical and Regulatory Science . Businesswire . 2019-05-26 . 2022-06-28 .
  25. Web site: CSL had eye on Vifor Pharma for a decade . Australian Financial Review . Lafrenz . Carrie . 2021-12-14 . 2022-06-28 .
  26. Web site: Vifor forges iron drug partnership with Fresenius in China . Pharmaphorum . Staines . Richard . 2020-02-20 . 2022-06-28 .
  27. Web site: Vifor Pharma jumps further into vascular calcification field, through acquisitions . The Pharma Letter . 2021-11-22 . 2022-06-28.
  28. Web site: Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance . Australian Financial Review . 2020-03-12 . 2022-06-28 .
  29. Web site: I've been diagnosed with iron deficiency, now what?. Hippocampus. 2020-11-18. 2022-05-20. Patterson. Amanda. Johnson. Jacklyn.
  30. Web site: fizer's Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market. Biospace. 2018-07-31. 2022-05-20.
  31. Web site: Kapruvia receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients. Biospace. 2022-02-25. 2022-05-20.
  32. Web site: Vifor Pharma's IV Ferinject reduces the need for further anemia treatment in kidney disease patients. ASN-Online. 2013-07-10. 2022-05-20.
  33. Web site: Fairness Opinion Vifor Pharma. IFBC. 2022-01-17. 2022-05-20.
  34. Web site: Indirect Comparison of Treatments for Secondary Hyperparathyroidism Through a Network Meta-Analysis. ASN-Online. 2020-10-22. 2022-05-20.
  35. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia. 2019-10-22. 2019-10-22. The Journal of Clinical Investigation. 10.1172/JCI129382 . Manolova . Vania . Nyffenegger . Naja . Flace . Anna . Altermatt . Patrick . Varol . Ahmet . Doucerain . Cédric . Sundstrom . Hanna . Dürrenberger . Franz . 130 . 1 . 491–506 . 31638596 . 6934209 .
  36. Web site: Vifor Pharma reports sustained growth in 2021. Biospace. 2022-02-17. 2022-05-20.
  37. Web site: CSL Tenders Offer to Buy Vifor Pharma for $11.7 Billion. Biospace. 2021-12-14. 2022-05-20. McKenzie. Heather.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "CSL Vifor".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.